GlaxoSmithKline's (GSK) Advair HFA Inhalation Aerosol is Now Available
More News related to GSK
- LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease
- GlaxoSmithKline (GSK) volatility Elevated at 43; shares near four-year low
- SAFE-BioPharma Announces Fast, Innovative Identity Proofing Procedure
- GlaxoSmithKline Named a 2008 100 Best Company by Working Mother Magazine
- alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
More News related to Corporate News
- Constar International (CNST) Announces Four-Year Agreement with Pepsi (PEP); Undertakes Restructuring Plan
- SandRidge Energy (SD) Acquires Additional Interests and Terminates Executive Well Participation Plan
- Range Resources (RRC) Reports Record Production, 19% YoY Increase
- Oracle (ORCL) CEO Says May Take Advantage of Slowing Economy to Buy Other Companies -WSJ
- Lehman CDS Auction Sets Price of 8.625c on Bonds; Sellers of Swaps Would Pay 91.375c on the Dollar
Advair HFA Inhalation Aerosol, a new formulation combining fluticasone propionate and salmeterol in a metered-dose inhaler (MDI) delivery device, is now available in pharmacies nationwide. Advair, a medicine used in the treatment of asthma, became available in 2001 as a dry-powdered inhaler known as Advair Diskus.
Advair HFA was developed and is marketed by GlaxoSmithKline (NYSE: GSK), a research-based pharmaceutical and a world leader in respiratory care. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Related Categories
Corporate NewsStocks Mentioned
-0.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
